New agents in the treatment of childhood leukemias and myelodysplastic syndromes |
| |
Authors: | Seth J. Corey |
| |
Affiliation: | (1) Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 853, 77030 Houston, TX, USA |
| |
Abstract: | Relapsed or refractory leukemia remains the most common therapeutic problem in pediatric oncology. Particularly challenging is the patient who has recurrence following a stem cell transplant. Insights into the molecular pathogenesis of the leukemias have produced an array of new agents. These new agents will be more selective in hitting their targets, and so their use will be more narrowly defined than with classical cytotoxic drugs. These new agents include all-trans retinoic acid, gemtuzumab ozogamicin, imatinib mesylate, rituximab, and a bevy of signal transduction inhibitors and therapeutic monoclonal antibodies. Other new agents, such as liposomal daunorubicin, PEG-asparaginase, or clofarabine, represent chemical modifications of established antileukemic drugs. Increasingly, molecular profiling will be used to guide the development and application of new drugs. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|